PharmaEssentia Corporation is a biopharmaceutical company focused on developing and commercializing therapies for myeloproliferative neoplasms (MPNs) and other hematological diseases. The company’s primary product is Ropeginterferon alfa-2b, marketed as BESREMi, which is an interferon therapy approved for the treatment of polycythemia vera (PV). PharmaEssentia is advancing its pipeline with clinical trials for essential thrombocythemia (ET) and other blood disorders. The company operates a cGMP biologics manufacturing facility in Taichung and has announced plans to establish a new manufacturing facility in Puerto Rico. Commercial operations span North America, Europe, Japan, Korea, Hong Kong, Beijing, and Singapore. Founded in 2003, the company was established by a group of Taiwanese-American executives and scientists to develop treatments for MPNs, hepatitis, and other diseases. PharmaEssentia partners with institutions such as Tech Tokyo for scientific research initiatives.

Summarised from the company's own disclosures, fiscal year ended Oct 2026

Industry Biotechnology Homepage pharmaessentia.com
Sector Healthcare IR page pharmaessentia.com/investors
Tags
hematology, oncology, interferon therapy, myeloproliferative neoplasms, polycythemia vera, essential thrombocythemia, biologics manufacturing, rare diseases, BESREMi, Ropeginterferon alfa-2b, Ropeginterferon alfa-2b-njft, P1101
Press page pharmaessentia.com/news

Metrics

Valuation  
Market cap NT$ 499.402B
Market cap (USD) $ 15.158B
P/E 53.77
PEG —
P/BV 12.20
P/S 20.29
P/OCF 196.08
P/FCF —
Dividend yield —
Turnover / mcap —
Returns  
ROE 17.0%
ROI 15.8%
ROIC 15.4%
Profit margin 32.3%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 26
Quality score 43.8%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Revenue 15.635B 9.735B 5.106B 2.882B 656.506M 557.257M 305.692M 26.236M 4.035M 5.473M 11.589M 13.356M 72.327M
Net profit 5.045B 2.966B -623.835M -1.375B -2.811B -1.948B -842.994M -1.04B -872.308M -844.918M -853.201M -853.106M -593.15M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Share price 470 615 — — — — — — — — — — —
Price performance 12m -0.24 — — — — — — — — — — — —

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Prompts

PharmaEssentia Corporation (ticker 6446.TW), listed in Taiwan.

ETFs Holding PharmaEssentia Corporation

ETF Weight in ETF Shares Market value As of
RCGE 0.52% 13,114 $ 510K Nov 18, 2026
FEMR 0.42% 15,608 $ 657.53K Jun 30, 2026
EMMF 0.40% 17,000 $ 715.082K Jun 30, 2026
DFSE 0.20% 27,704 $ 1.147M Nov 12, 2026
DEXC 0.12% 7,885 $ 326.454K Nov 12, 2026
DFEM 0.10% 222,554 $ 9.214M Nov 12, 2026
DFAE 0.10% 210,826 $ 8.729M Nov 12, 2026
DFAX 0.04% 107,718 $ 4.46M Nov 12, 2026
DFEV 0.02% 12,202 $ 505.186K Nov 12, 2026
AVXC 0.01% 1,230 $ 47.843K Nov 16, 2026